ROS1 and neoplasm: ROS1 fusions have been identified on NSLCL line HCC78 (SLC34A2-ROS1) and on tumor sample (CD74-ROS1), leading to constitutive kinase activation and conferring sensitivity in vitro to TKIs [28].